Mr. Wang has served as the interim Chief Executive Officer of Orlucent since 2012. As part of Wang Ventures, he has researched, advised and invested in medical device, financial and technology start-up companies, including six biomedical companies. Until 2017, Mr. Wang was a Board and Executive Committee Member of Penumbra, Inc., a highly successful interventional therapy company. Mr. Wang received a B.S. degree from the University of Southern California.

Dr. Shachaf was the founding Chief Executive Officer of Orlucent and since 2012 has served as the President and Chief Science Officer. She is a well-known cell biologist and former instructor at Stanford University School of Medicine who has made ground-breaking discoveries in cancer research. Her life science career has included extensive work in preclinical cancer imaging, cancer biology and nanotechnology imaging. Dr. Shachaf is also a popular speaker at scientific conferences throughout the world and has published more than 17 journal articles. Her education includes: Post doctorate fellow: Stanford University, Medical Oncology, Ph.D: Israel Institute of Technology, Molecular Medicine, M.Sc: Israel Institute of Technology, Genetics, and B.Sc.: University of Haifa, Israel, Biology.